{
    "nctId": "NCT02965443",
    "officialTitle": "Effectiveness of Dapagliflozin + Saxagliptin to Revert From a Basal-bolus Insulin Treatment (BBIT) Regimen to a Basal Supported Oral Therapy (BOT) in Patients With Type 2 Diabetes",
    "inclusionCriteria": "* Type 2 diabetes\n* Age 18 - 75 years\n* Anti-GAD antibodies negative (Glutamic Acid Decarboxylase)\n* C-peptide levels \u2265 1.5 ng/mL\n* Fasting blood glucose \\> 126 mg/dl\n* HbA1c 8.0 - 10.5 %\n* BMI 25.0 - 45.0 kg/m2\n* Previous therapy with BBIT (basal insulin and at least once daily bolus insulin)\n* Must have minimum age of 18 Years\n* Must have maximum age of 75 Years",
    "exclusionCriteria": "* Use of any oral antidiabetic treatment except for metformin (i.e., sulphonylureas, DPP-IV inhibitors, thiazolidinediones, SGLT-2 inhibitors (Sodium dependent glucose transporter) or GLP-1 analogues (glucagone like peptide) within the last three months prior to Screening\n* Repeated episodes of severe hypoglycaemia within the last six months prior to Screening\n* History of diabetic ketoacidosis, precoma diabetica, or diabetic coma\n* Treatment with any other investigational drug within the last three months before Screening\n* Acute infections within the last four weeks prior to Screening\n* Recurrent urogenital infections\n* History of pancreatitis\n* Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures\n* History of severe or multiple allergies\n* Concomitant participation in other clinical trials\n* Type 1 diabetes\n* Cardiovascular disease Clinically relevant ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs. Percutaneous coronary intervention within the past 6 months. Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke.\n\nUncontrolled unstable angina pectoris or history of pericarditis, myocarditis, endocarditis. Congestive heart failure NYHA (New York Heart Association) class III or IV. Increased risk of thromboembolism, e.g. subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.\n\n* Malignancy including leukemia and lymphoma within the last 5y.\n* Liver disease such as cirrhosis or chronic active hepatitis.\n* Significant renal dysfunction (see also exclusion criteria laboratory abnormalities).\n* State after kidney transplantation\n* Endocrine disease:\n\nAcromegaly or treatment with growth hormone or similar drugs. Chronic oral or parenteral corticosteroid treatment (\\>7 consecutive days of treatment) within 8 weeks; thyroid hormone replacement is allowed if the dosage has been stable for at least 3 months and the TSH is within normal limits\n\n\u2022Any of the following significant laboratory abnormalities: eGFR (as calculated by the MDRD equation) \\< 60 ml/min at Screening Fasting triglycerides \\>700 mg/dl (\\>7.9 mmol/l)\n\n* Systolic blood pressure outside the range of 100-160 mmHg or diastolic blood pressure above 95 mmHg at Screening\n* History of active substance abuse (including alcohol \\> 40g/day) within the past 2 years.\n* Pregnancy or childbearing potential without adequate contraception\n* Present therapy with systemic steroids\n* Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI\u00b4s (selective serotonin reuptake inhibitor)\n* Potentially unreliable subjects, and those judged by the investigator to be unsuitable for the study.\n* Contraindications for Magnetic resonance (MR) scanning such as persons with cardiac pacemaker and implants out of metal or claustrophobia"
}